Psoriasis is a chronic immune-mediated inflammatory skin disease marked by accelerated keratinocyte turnover and recurrent erythematous scaly plaques.
Alumis reported that 54% of psoriasis patients achieved complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, with 75% achieving PASI 90. The company plans to submit an NDA for envudeucitinib in Q4 2026.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
InnoCare's TYK2 inhibitor fadeucravacitinib met primary and secondary endpoints in a Phase 3 psoriasis trial, with a favorable safety profile. InnoCare plans to seek regulatory approval.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
FDA approved roflumilast cream 0.3% (Zoryve) for plaque psoriasis in children age 2+, the first once-daily steroid-free topical for that group. A meta-analysis found it improved IGA scores and was well tolerated.
In the BE RADIANT phase 3b trial, bimekizumab provided greater and durable improvements in patient-reported symptoms, skin clearance, and quality of life over 3 years compared with secukinumab in moderate to severe plaque psoriasis. At week 4, significantly more patients on bimekizumab achieved complete absence of itching, skin pain, and scaling. The benefits were sustained through 3 years, including after patients switched from secukinumab.
A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780929 |
A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis |
RECRUITING | NA |
| NCT07746583 |
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice |
RECRUITING | |
| NCT07746479 |
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) |
COMPLETED | PHASE3 |
| NCT07736651 |
Anti Inflammatory Diet With Physical Therapy on Psoriasis |
RECRUITING | NA |
| NCT07724366 |
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07719530 |
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis |
RECRUITING | PHASE2 |
| NCT07713212 |
Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07712731 |
HPP737 in Adult Patients With Plaque Psoriasis |
COMPLETED | PHASE3 |
| NCT07712705 |
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. |
COMPLETED | PHASE3 |
| NCT07709169 |
Psoriasis and Its Impact on Quality of Life Among Psoriatic Patients |
COMPLETED |
